Stephen L. Silvestro - Mar 1, 2024 Form 4 Insider Report for OptimizeRx Corp (OPRX)

Role
Chief Commercial Officer
Signature
/s/ Marion Odence-Ford, by Power of Attorney
Stock symbol
OPRX
Transactions as of
Mar 1, 2024
Transactions value $
-$10,655
Form type
4
Date filed
3/6/2024, 04:20 PM
Previous filing
May 6, 2024
Next filing
Apr 24, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OPRX Common Stock Options Exercise $0 +1.93K +41.03% $0.00 6.62K Mar 1, 2024 Direct F1
transaction OPRX Common Stock Tax liability -$10.7K -668 -10.08% $15.95 5.96K Mar 1, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OPRX Restricted Stock Units Options Exercise $0 -1.93K -49.99% $0.00 1.93K Mar 1, 2024 Common Stock 1.93K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock.
F2 These shares were withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended.
F3 The restricted stock units vest in three equal annual installments beginning March 1, 2023, the first anniversary of the grant date.

Remarks:

The filing of this Statement shall not be construed as an admission (a) that the person filing this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be filed by such person.